Hepion Pharmaceuticals Executive Chairman Buys $250K Stock at Significant Premium
CTRVP is trading near its 52-week low of $0.001 (0.0% above the low).
Summary
Vincent S. LoPriore, Executive Chairman, Director, and 10% Owner of Hepion Pharmaceuticals, purchased $250,000 worth of common stock at a significant premium to the current market price, signaling strong conviction.
Key Events · Ownership and Investor Activity · CTRVP
-
Executive Chairman Invests at Significant Premium
Vincent S. LoPriore, Executive Chairman, Director, and 10% Owner, purchased $250,000 worth of common stock at $0.04 per share, a substantial premium to the current market price of $0.0013.
-
Substantial Capital Infusion
This purchase, totaling 6,250,000 shares, represents a significant capital infusion for Hepion Pharmaceuticals, following a recent $700,000 private placement and another insider purchase, both at the $0.04 price point.
-
Indirect Ownership
The shares were acquired indirectly through Gravitas Capital LP and Invictus Capital Advisors Pension Plan, entities where Mr. LoPriore has voting and dispositive control.
Analysis · CTRVP · Life Sciences
This is a highly significant insider purchase for Hepion Pharmaceuticals. Executive Chairman, Director, and 10% Owner Vincent S. LoPriore invested $250,000 in common stock. Notably, these shares were acquired at $0.04 each, a substantial premium compared to the current market price of $0.0013. This strong vote of confidence from a key insider, especially at such a premium, is a powerful positive signal for a company with a super-nano market capitalization. This purchase, alongside a recent $700,000 private placement and another insider buy by the Interim CEO, both at the $0.04 price point, suggests a concerted effort to fund and stabilize the company at a valuation significantly above its current trading price. Such a large insider investment at a premium can be critical for a micro-cap company, potentially alleviating immediate liquidity concerns and indicating a strong belief in future prospects.
At the time of this filing, CTRVP was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $476.4K. The 52-week trading range was $0.00 to $0.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.